Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

This study is currently recruiting participants.
Verified October 2013 by Masonic Cancer Center, University of Minnesota
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT01581970
First received: April 18, 2012
Last updated: October 8, 2013
Last verified: October 2013

April 18, 2012
October 8, 2013
June 2012
July 2015   (final data collection date for primary outcome measure)
  • Progression Free Survival [ Time Frame: At 2 Years ] [ Designated as safety issue: No ]
    Progression of disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
  • Overall Survival [ Time Frame: At 2 Years ] [ Designated as safety issue: No ]
    Defined as patient alive at this time period.
Same as current
Complete list of historical versions of study NCT01581970 on ClinicalTrials.gov Archive Site
  • Ratio of Tregs to Effector Cells [ Time Frame: 6 Weeks Post Treatment with Cyclophosphamide ] [ Designated as safety issue: No ]
    the ratio of Tregs to effector cells (NK cells, CD8+ lymphocytes, macrophages/monocytes) in tumor tissue as measured by immune-histochemistry (IHC) of tumor tissue
  • Ratio of Tregs to Natural Killer (NK) Cells [ Time Frame: 6 Weeks Post Treatment with Cyclophosphamide ] [ Designated as safety issue: No ]
    the Ratio of Tregs to NK cells in peripheral blood as measured by flow cytometry
  • Myeloid-derived suppressor cells in Tumor Tissue [ Time Frame: Week 6 ] [ Designated as safety issue: No ]
    Myeloid-derived suppressor cells in tumor tissue as measured by immune-histochemistry (IHC)
  • Quality of Life Scores [ Time Frame: Comparison from Baseline to Week 6 and Week 12 ] [ Designated as safety issue: No ]
    Comparison of health related quality of life scores as measured by FACT-G: Functional Assessment of Cancer Therapy - General (constitutes the core of all subscales; the FACT-G can be used with patients of any tumor type)questionnaire.
Same as current
Not Provided
Not Provided
 
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
Potentiation of Cetuximab by Tregs Depletion With Metronomic Cyclophosphamide in Metastatic Squamous Cell Cancers of Head and Neck

This is a feasibility study to assess the effectiveness of cetuximab when administered with low dose oral cyclophosphamide. Patients with metastatic squamous cell cancer of head and neck who have progressed on first line chemotherapy other than a cetuximab containing regimen will be treated with standard of care weekly cetuximab and twice daily low dose oral cyclophosphamide for 12 weeks.

In this study, patients with head and neck squamous cell carcinoma (HNSCC) will be given low-dose cyclophosphamide in combination with standard of care cetuximab. Tumor biopsies will be collected before and six weeks after treatment for measurement of tumor infiltration by effector cells, including CD8+ T cells, natural killer (NK) cells, and monocytes. In addition, the proportion of Tregs to effector cells will be measured in peripheral blood at the same time points.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Head and Neck Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Drug: Cyclophosphamide
    Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
    Other Name: Cytoxan
  • Drug: Cetuximab
    The initial dose of cetuximab 400 mg/m^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m^2 intravenously (IV) over 60 minutes.
    Other Name: Erbitux
Experimental: Patients Treated with Cetuximab/Cyclophosphamide
Safety population as defined by all patients receiving at least one treatment with cyclophosphamide on Day 1.
Interventions:
  • Drug: Cyclophosphamide
  • Drug: Cetuximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
15
July 2015
July 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically documented squamous cell carcinoma of the head and neck (irrespective of site of primary - nasopharyngeal, oral cavity, oropharyngeal, laryngeal or unknown primary) that is metastatic/incurable and has progressed on a first line chemotherapy regimen.
  • Progression of measurable disease within the last 6 weeks based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria
  • If the patient has received prior treatment with anti-epidermal growth factor receptor (EGFR) therapy as a part of definitive therapy concurrent with radiation, the time from the last cetuximab exposure must be > 180 days.
  • Must be at least 30 days from prior treatment and have recovered from the reversible effects of previous anti-cancer treatment
  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
  • Adequate bone marrow, renal and hepatic function within 14 days of study enrollment defined as:

    • Bone marrow: White blood cells (WBC) > 3,000/uL; absolute neutrophil count > 1,500/uL; platelets > 100,000/uL
    • Renal: creatinine ≤ 2.5 times the institutional upper limit of normal (ULN)
    • Hepatic: total bilirubin < 1.5 X institutional ULN; aspartate aminotransferase/alanine aminotransferase (AST[SGOT] and ALT[SGPT]) < 2.5 X institutional ULN
    • Albumin > 3.0 gm/dL
  • Women of childbearing potential and fertile men must be willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for 60 days after the last dose of study drug.
  • Voluntary written consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care

Exclusion Criteria:

  • Pregnant or lactating - females of child bearing potential must have a negative pregnancy test within 14 days of study enrollment as cyclophosphamide is Pregnancy Category D
  • History of another active primary invasive cancer within the previous 2 years, excluding non-melanoma skin cancer
  • The patient is receiving concurrent treatment with other anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiotherapy (RT), chemoembolization, or targeted therapy. Patients receiving palliative radiation therapy to bony metastases prior to the first dose of study medication are eligible.
  • Chronic steroid dependence
  • Known HIV-positive patients and those with other acquired/inherited immunodeficiency hepatitis B, hepatitis C, connective tissue disease, or other clinical diagnosis, ongoing or intercurrent illness that in the Investigator's opinion should preclude the subject from participation
  • History of gastrointestinal disease causing malabsorption or obstruction such as, but not limited to Crohn's disease, celiac sprue, tropical sprue, bacterial overgrowth/blind loop syndrome, gastric bypass surgery, strictures, adhesions, achalasia, bowel obstruction, or extensive small bowel resection
  • Inability to take medications by mouth
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition
  • Active autoimmune disease, chronic inflammatory condition, conditions requiring concurrent use of any systemic immunosuppressants or steroids. Mild-intermittent asthma requiring only occasional beta-agonist inhaler use or mild localized eczema will not be excluded.
  • Previous allo-transplant of any kind
Both
18 Years and older
No
Contact: Gautam Jha, M.D. 612-624-5373 jhaxx014@umn.edu
United States
 
NCT01581970
2012LS002
No
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Not Provided
Principal Investigator: Gautam Jha, M.D. Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP